四方精創(300468.SZ):益志控股及李琳減持期屆滿 合計減持293.46萬股
格隆匯11月15日丨四方精創(300468.SZ)公佈,公司於2019年11月15日收到股東益志控股、李琳出具的《關於股份減持計劃期滿暨實施情況的告知函》,截至公告日上述減持計劃期限已屆滿,益志控股累計減持281.46萬股,李琳累計減持12萬股;合計減持293.46萬股。
上述減持計劃實施過程中,由於公司回購股權激勵計劃限制性股票,公司總股本由1.94億股變更為1.89億股,益志集團控股有限公司此次減持後持有公司1240.43萬股,佔公司總股本的6.56%;公司回購了李琳有限售條件股份共計71.3萬股,此次減持後李琳持有公司股份36萬股,佔公司總股本的0.19%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.